Phase I Clinical Trials Offer Patients More Benefits Than Ever Before
The OHC Research Department’s complex clinical trial menu provides an opportunity for patients in and around the Tri-state to participate in innovative studies which include targeted therapies. OHC’s history of successful participation in cutting-edge clinical trials has provided the OHC Research Department with the opportunity to open numerous Phase I clinical trials in the past year.
A Phase I clinical trial is a trial that investigates the safety and efficacy of a new treatment or combination of treatments. In order to obtain FDA approval, all drugs (and combinations of drugs) must be rigorously tested in the clinical trial setting. Currently, OHC is enrolling patients to nine Phase I Clinical Trials.
If eligible, Phase 1 Clinical Trials are a great option for patients.
“With new agents that target specific abnormalities in a patient’s tumor, better tests to identify those abnormalities and more sophisticated clinical trial designs, today’s phase I trials in cancer offer patients a greater likelihood of benefit than ever before,” said ASCO President Peter Paul Yu, MD, FACP, FASCO. “Patients shouldn’t shy away from phase I trials and doctors should present these trials as options for eligible patients throughout the period of active cancer treatment, not only when all other treatment options have failed.”
OHC’s research menu has continued to evolve in order to accommodate the many disease types that are seen in our clinics. By participating in these trials, we are offering our patients a chance to try the newest, most promising investigational products for their disease.
For more OHC Clinical Research Trial information, contact:
Lynnetta Hart, BS, M.Ed, CCRC
OHC Research Program Director
513-751-2273 ext. 27101